

CORE AREAS FOR EVALUATION

- **Toxicokinetics** (ADME)
- **Genotoxicity**
- **Toxicity** (subchronic, chronic, carcinogenicity)
- **Reproductive & Developmental toxicity**
- **Additional studies** (immunotoxicity, neurotoxicity, human, etc)

OBJECTIVES

- Implementation of characterisation of hazard
- Dose response data for risk characterisation

Design Considerations – Toxicity studies

Rationale

- Tiered approach (balancing data requirements against other considerations)
- Experimental studies and human data

❖ Design of toxicological studies – Issues to consider

- compliance with EU standards & regulations (i.e. welfare standards)
- principle of the 3 Rs and animal welfare
- toxicity studies should comply to international agreed test guidelines (e.g. OECD) and performance standards (e.g. GLP)
- Administration route: oral

Committed *since 2002*
to ensuring that Europe's food is safe



Toxicokinetics (ADME)

David Gott

Vice-chair of the ANS Panel

Chair & Rapporteur - WG Guidance on Food Additives

Stakeholders workshop
21 September 2012, Brussels

OBJECTIVE

Describe the systemic exposure of the food additive and its relationship to dose levels.

RATIONALE

Selection for appropriate species & doses for toxicity testing

❖ Aims of toxicokinetics testing:

- determine systemic absorption to the chemical and its metabolites
- understanding of processes involved in ADME
- define possible species differences

❖ End-points of interest:

- systemic exposure/systemic availability
- absorption, distribution, metabolism
- mechanisms of toxicity

Other considerations:

- toxicologically relevant constituents
- matrix effect
- **negligible absorption**

Demonstration of negligible absorption either through experimental studies or from theoretical considerations

CONSIDERATIONS

- **Physicochemical parameters:**

chemical structure, molecular weight, octanol water partition coefficient, aqueous solubility, molecular shape, charge & dissociation constants

- **Study design parameters:**

% of absorption, robustness of study design and performance, sensitivity & specificity of methods of detection, detection limits, amount in faeces, dose accountancy

- **Other parameters:**

likelihood of persistence in tissues, predicted metabolic stability, results of tier 1 testing

TIER 1 (applicable to all additives)

Absorption studies & *in vitro* gastrointestinal metabolism

❖ **End-points of interest:**

- Absorption from GI tract
- Stability in GI tract

❖ **Testing requirements:**

- absorption (*in vitro*, *in vivo* & *ex vivo* models)
- stability of the compound (*in vitro* GI metabolism & other models)

TIER 2 (applicable to additives with systemic availability)

**Define distribution, metabolism & excretion,
and other toxicokinetic parameters (single dose)**

❖ **End-points of interest:**

- 'where it goes'
- 'what happens to it'
- 'how quickly it is removed'

❖ **Testing requirements:**

- *in vivo* assessment of ADME
- Toxicokinetics (OECD TG 417)

TIER 3 (triggered by limited excretion or bioaccumulation)

Define toxicokinetic parameters (repeated dose)

❖ **End-points of interest:**

- ADME (repeated dose-animals)
- Other studies (predict ADME in humans)
- Volunteer studies (humans)

❖ **Testing requirements:**

- repeated dose studies in animals
- human kinetic studies (volunteer studies)